LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Начало・Списък с акции・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Затворен

СекторЗдравеопазване

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	-0.79% downside

Настроения в новините

By Acuity

50%

155 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

131.5 / 131.92 Подкрепа & съпротива

Intra-Cellular Therapies Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.05.2026 г., 22:47 ч. UTC

Горещи акции

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15.05.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15.05.2026 г., 22:00 ч. UTC

Значими двигатели на пазара

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15.05.2026 г., 18:09 ч. UTC

Значими двигатели на пазара

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15.05.2026 г., 16:02 ч. UTC

Печалби

Значими двигатели на пазара

Forward Industries Shares Fall on New Debt as Solana Value Drops

15.05.2026 г., 14:55 ч. UTC

Значими двигатели на пазара

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15.05.2026 г., 14:43 ч. UTC

Значими двигатели на пазара

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15.05.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15.05.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15.05.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15.05.2026 г., 21:16 ч. UTC

Пазарно говорене

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 20:19 ч. UTC

Горещи акции

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15.05.2026 г., 19:41 ч. UTC

Придобивния, сливания и поглъщания

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15.05.2026 г., 19:35 ч. UTC

Пазарно говорене

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15.05.2026 г., 18:35 ч. UTC

Печалби

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15.05.2026 г., 17:28 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15.05.2026 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15.05.2026 г., 16:24 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Silver Plunges on Inflation Worries -- Market Talk

15.05.2026 г., 15:20 ч. UTC

Печалби

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15.05.2026 г., 14:33 ч. UTC

Пазарно говорене

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Intra-Cellular Therapies Inc Прогноза

Ценова цел

By TipRanks

-0.79% надолу

12-месечна прогноза

Среден 130.83 USD -0.79%

Висок 132 USD

Нисък 118 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Intra-Cellular Therapies Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Intra-Cellular Therapies Inc през последните 3 месеца.

Техническа оценка

By Trading Central

131.5 / 131.92Подкрепа & съпротива

There is one bullish event.

There are no events.

Настроение

By Acuity

155 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.